3′-Deoxy-3′-[18F]fluorothymidine (FLT) uptake in breast cancer cells as a measure of proliferation after doxorubicin and docetaxel treatment

Nuclear Medicine and Biology

Volumn 36, Issue 2, 2009, Pages 163-169

  Dittmann, Helmut ^a   Jusufoska, Ajnur ^a   Dohmen, Bernhard Matthias ^a   Smyczek Gargya, Brigitte ^a   Fersis, Nikos ^a   Pritzkow, Maren ^a   Kehlbach, Rainer ^a   Vonthein, Reinhard ^a   Machulla, Hans Juergen ^a   Bares, Roland ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Breast cancer; Docetaxel; Doxorubicin; Fluorothymidine; Positron emission tomography

Indexed keywords

3' FLUOROTHYMIDINE; CELL MARKER; DOCETAXEL; DOXORUBICIN; FLUORINE 18; THYMIDINE KINASE 1; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT; TAXOID; THYMIDINE;

ANALYSIS OF VARIANCE; ARTICLE; BLAND ALTMAN DIFFERENCE PLOT; BREAST CANCER; CELL CYCLE S PHASE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOSE RESPONSE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE TRACING; POSITRON EMISSION TOMOGRAPHY; STATISTICAL ANALYSIS; BREAST TUMOR; CHEMISTRY; DRUG EFFECT; FEMALE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; RADIOPHARMACEUTICALS; S PHASE; TAXOIDS; THYMIDINE;

EID: 59649116913     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.10.012     Document Type: Article

References (33)

1. Kim R., Osaki A., and Toge T. Current and future roles of neoadjuvant chemotherapy in operable breast cancer. Clin Breast Cancer 6 (2005) 223-232
2. Bear H.D., Anderson S., Smith R.E., Robidoux A., Kahlenberg M.S., Margolese R.G., et al. A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP B-27. Breast Cancer Res Treat 88 Suppl 1 (2004) 26A
3. Thomas E., Holmes F.A., Smith T.L., Buzdar A.U., Frye D.K., Fraschini G., et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 22 (2004) 2294-2302
4. Shields A.F., Grierson J.R., Dohmen B.M., Machulla H.J., Stayanoff J.C., Lawhorn-Crews J.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 (1998) 1334-1336
5. Kong X.B., Zhu Q.Y., Vidal P.M., Watanabe K.A., Polsky B., Armstrong D., et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 36 (1992) 808-818
6. Sherley J.L., and Kelly T.J. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 263 (1988) 8350-8358
7. Parker W.B., and Cheng Y.C. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48 (1990) 381-395
8. Yang X.L., and Wang A.H. Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther 83 (1999) 181-215
9. Abal M., Andreu J.M., and Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 3 (2003) 193-203
10. Romain S., Spyratos F., Descotes F., Daver A., Rostaing-Puissant B., Bougnoux P., et al. Prognostic of DNA-synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, M0 breast cancers: a retrospective multicenter study. Int J Cancer 87 (2000) 860-868
11. 18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 31 (2004) 720-724
12. 18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 65 (2005) 10104-10112
13. Pio B.S., Park C.K., Pietras R., Hsueh W.A., Satyamurthy N., Pegram M.D., et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8 (2006) 36-42
14. 18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34 (2007) 1339-1347
15. Bardot V., Dutrillaux A.M., Delattre J.Y., Vega F., Poisson M., Dutrillaux B., et al. Purine and pyrimidine metabolism in human gliomas: relation to chromosomal aberrations. Br J Cancer 70 (1994) 212-218
16. Cole P.D., Smith A.K., and Kamen B.A. Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs. Cancer Chemother Pharmacol 50 (2002) 111-116
17. Schwartz J.L., Tamura Y., Jordan R., Grierson J.R., and Krohn K.A. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 44 (2003) 2027-2032
18. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 29 (2002) 1462-1469
19. Nabholtz J.M. Docetaxel-anthracycline combinations in metastatic breast cancer. Breast Cancer Res Treat 79 Suppl 1 (2003) 3-9
20. Yung W.K. In vitro chemosensitivity testing and its clinical application in human gliomas. Neurosurg Rev 12 (1989) 197-203
21. Bland J.M., and Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 8476 (1986) 307-310
22. Grierson J.R., Schwartz J.L., Muzi M., Jordan R., and Krohn K.A. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nucl Med Biol 31 (2004) 829-837
23. 18F]fluorothymidine into L5178Y tumors in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 32 (2005) 257-263
24. Rasey J.S., Grierson J.R., Wiens L.W., Kolb P.D., and Schwartz J.L. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43 (2002) 1210-1217
25. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63 (2003) 3791-3798
26. Munch-Petersen B., Tyrsted G., and Cloos L. Reversible ATP-dependent transition between two forms of human cytosolic thymidine kinase with different enzymatic properties. J Biol Chem 268 (1993) 15621-15625
27. van Waarde A., Been L.B., Ishiwata K., Dierckx R.A., and Elsinga P.H. Early response of sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells. J Nucl Med 47 (2006) 1538-1545
28. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57 (1999) 727-741
29. Demidenko Z.N., Halicka D., Kunicki J., McCubrey J.A., Darzynkiewicz Z., and Blagosklonny M. Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel. Cancer Res 65 (2005) 4401-4407
30. Direcks W.G.E., Berndsen S.C., Proost N., Peters G.J., Balzarini J., Spreeuwenberg M.D., et al. Molthoff CFM [(18)F]FDG and [(18)F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study. Br J Cancer 99 (2008) 481-487
31. Rasey J.S., Grierson J.R., Wiens L.W., and Kolb P.E. Uptake of labeled FLT correlates with thymidine kinase (TK1) activity in human tumor cells. J Nucl Med 41 Suppl 1 (2000) 36P
32. Demarcq C., Bastian G., and Remvikos Y. BrdUrd/DNA flow cytometry analysis demonstrates cis-diamminedichloroplatinum (II)-induced multiple cell-cycle modifications on human lung carcinoma cells. Cytometry 13 (1992) 416-422
33. Kinsella A.R., Smith D., and Pickard M. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer 75 (1997) 935-945